Ren and colleagues reported that PI3K/Akt blockade in combination with Bcl-xL inhibition resulted in synergistic apoptosis, in particular in PTEN-mutant prostate cancer cells, whereas single PI3K/Akt inhibition did not [57]. Here, BCL2L1 is linked to prostate cancer.